Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era
Carolina Digital Repository (University of North Carolina at Chapel Hill) · 17.12.2024
DOI: 10.17615/pf72-y335 ↗Kurz gefasst
Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 17.12.2024. Verfasst von Radhika Gangaraju und 35 weiteren Autor:innen.
Abstract (Originalsprache)
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab is maintained with subsequent treatment courses has not been studied. Using the United States Thrombotic Microangiopathy Consortium (USTMA) retrospective iTTP registry, we evaluated clinical relapse free survival (RFS) with subsequent courses of rituximab treatment in multiply relapsing patients. Separately, we evaluated overall RFS (composite of time to clinical relapse, ADAMTS13 relapse, or preemptive rituximab) in a prospective iTTP cohort from the Johns Hopkins University and the University of Minnesota. In the USTMA registry, median clinical RFS was shorter after the 2nd or subsequent rituximab-treated episode compared to the first (2.1 vs 6.0 years, P = 0.04). White patients' clinical relapse risk after the second and subsequent rituximab courses was not significantly different compared to the first [HR=1.86 (95% CI 0.22-15.80), P=0.57], while for Black patients, clinical relapse risk was significantly higher after the second or subsequent courses [HR=2.82 (95% CI 1.52-5.24), P=0.001]. In the prospective cohort, overall RFS progressively shortened after each episode of rituximab treatment with the first episode having the longest RFS (2.8 years IQR 2.0-6.0) and this loss of response durability was most pronounced in Black patients. The durability of rituximab's effect declines with subsequent treatments, which is more pronounced in Black patients who may benefit from closer monitoring and alternative immunomodulatory approaches such as maintenance rituximab and consideration of other agents.
Schlagwörter
Zitieren
APA
Gangaraju, R., Masias, C., Evans, M. D., Chaturvedi, S., Woods, Ryan, Park, Y. A., Liles, D., Johnson, Andrew, Kreuziger, L. B., Ridder, G. D., Akwaa, F., Sadler, J. E., McCrae, K. R., Kocher, N. K., Brown, J., Go, R. S., Raval, J. S., …, & Upreti, H. V. (2024). Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/pf72-y335
Vancouver
Gangaraju R, Masias C, Evans MD, Chaturvedi S, Woods, Ryan, et al. Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2024. doi:10.17615/pf72-y335
BibTeX
@article{Gangaraju2024,
author = {Gangaraju, Radhika and Masias, Camila and Evans, Michael D. and Chaturvedi, Shruti and Woods and Ryan and Park, Yara A. and Liles, Darla and Johnson and Andrew and Kreuziger, Lisa Baumann and Ridder, Gustaaf de and Akwaa, Frank and Sadler, J. Evan and McCrae, Keith R. and Kocher, Nicole K. and Brown, Jenna and Go, Ronald S. and Raval, Jay S. and Mazepa, Marshall A. and Antun, Ana G. and Gibson, Briana and Clover, Todd and Metjian, Ara D. and Lim, Ming Yeong and Fatola, Ayotola and Zheng, X. Long and Farland, Andrew Matthew and Cataland, Spero R. and Kasthuri, Raj S. and Consortium, USTMA and Davis and Elizabeth and Sridharan, Meera R. and Eubanks, Susan and Upreti, Harsh Vardhan},
title = {Relapse Free Survival Progressive Shortens in a Subset of Black patients with Immune TTP Treated in the Rituximab Era},
journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
year = {2024},
doi = {10.17615/pf72-y335}
}
EUVIMED